| |
Expert Commentary offers you the latest interviews with key opinion leaders
|
|
|
|
|
| |
Controversies in the Treatment and Prevention of VTE With Warfarin
In this Expert Commentary, Dr Samuel Goldhaber discusses recent data on the utilization of warfarin for the treatment and prophylaxis of venous thromboembolism (VTE), as well as the issues and clinical opinions surrounding these data. Current controversies that involve warfarin include pharmacogenetic management, dosing issues, duration of therapy, emerging agents that may supplant warfarin, and drug-drug interactions, among others. This educational activity draws further attention to this timely clinical topic that has received much recent attention. This activity also addresses the barriers to the implementation of thromboprophylaxis in medically ill patients and explains the benefits of thromboprophylaxis in reducing the morbidity and mortality associated with VTE in these patients.
Read full commentary
|
|
|
| |
| |
Upcoming Trials in VTE
In this expert commentary, Dr Kakkar provides a detailed overview of recent clinical trials that will have an impact on preventing VTE in certain patient populations
Read full commentary
|
|
|
| |
| |
Antithrombotic Therapy Considerations in Special Patient Populations
In this two part expert commentary, Dr Edith A. Nutescu discusses antithrombotic therapy considerations relevant to obese patients and patients with impaired renal function.
Read full commentary
|
|
|
| |
| |
Orthopedic Thromboprophylaxis: The Timing of Administration
In this expert commentary, Dr Warwick discusses the timing of VTE prophylaxis administration for orthopedic surgeries. He discusses the numerous implications that are associated with assessing a patient’s risk for developing thrombosis after surgery.
Read full commentary
|
|
|
| |
| |
Pharmacoeconomics of Low-molecular-weight Heparin Versus Unfractionated Heparin
In this expert commentary, Prof Lee Vermeulen discusses the economic benefits of using thromboprophylaxis in acutely ill medical patients.
Read full commentary
|
|
|
| |
| |
The Design of Clinical Trials
In this expert commentary, Dr Marc Cohen answers questions on the design and execution of clinical trials. He discusses the different kinds of clinical trials and the advantages and disadvantages of each type.
Read full commentary
|
|
|
| |
| |
Patient Registries
In this expert commentary, Dr Eagle describes the types of information that can be derived from patient registries, such as the adoption of new technology or practice guidelines.
Read full commentary
|
|
|
| |
| |
Duration of Prophylaxis in Medical Patients
In this expert commentary, Dr Victor F. Tapson describes the types of medical patients studied in VTE clinical trials and the variety of pharmacological and nonpharmacological options available for prophylaxis of VTE. He discusses the risks and benefits associated with each option, including heparin, low-molecular-weight heparin, warfarin, fondaparinux, ximelagatran, and mechanical methods of prophylaxis.
Read full commentary
|
|
|
| |
| |
Identifying Patients with DVT or PE: Current Standards and Future Directions
In this expert commentary, Dr Amir Jaffer discusses current standards and future directions with regard to diagnosis of patients with DVT or PE. VTE is the 3rd leading cause of cardiovascular death in the United States, with an estimated 2 million cases of DVT occurring every single year.
Read full commentary
|
|
|
| |
| |
Aspirin Resistance in Thrombosis Management
In this expert commentary, Deepak L. Bhatt, MD, Director of the Interventional Cardiovascular Fellowship at the Cleveland Clinic Foundation in Cleveland, Ohio, discusses the current data available on aspirin resistance and emerging insights on how these data should influence clinical decision-making.
Read full commentary
|
|
|
| |
| |
Interview with Joseph A. Caprini, MD
In this expert commentary, Dr Caprini discusses the guidelines based on The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Prophylaxis for Venous Thromboembolism.
Read full commentary
|
|
|
| |
| |
Interview with Jonathan L. Halperin, MD
In this interview, Dr Jonathan Halperin addresses key issues surrounding ximelagatran clinical trials and the decision by the Food and Drug Administration (FDA) not to grant new drug application (NDA) approval.
Read full commentary
|
|
|
| |
| |
Interview with Kenneth W. Mahaffey, MD
The following program, including a trial synopsis and expert commentary by Dr Kenneth Mahaffey, provides an overview of the key findings of SYNERGY and insight into their potential impact on current clinical practice.
Read full commentary
|
|
|
| |
|